Algeria vs India: Average cost of multi drug-resistant tuberculosis treatment
Algeria
440 constant 2022 US$
in 2022
India
400 constant 2022 US$
in 2024
Algeria rank
85th
India rank
87th
Average cost of multi drug-resistant tuberculosis treatment over time
- Algeria
- India
How they compare
Algeria currently reports 440 constant 2022 US$ against 400 constant 2022 US$ in India, a difference of 40 constant 2022 US$.
That makes Algeria's figure about 1.1 times India's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was India ahead.
Algeria ranks 85th and India ranks 87th of 92 countries.
Across the 2 decades both report, Algeria averaged higher in 1 and India in 1.
Head to head by decade
| Decade | Algeria | India | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 862.5 constant 2022 US$ | 1,650 constant 2022 US$ | 787.5 constant 2022 US$ | India |
| 2020s | 680 constant 2022 US$ | 472 constant 2022 US$ | 208 constant 2022 US$ | Algeria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Algeria or India?
- Algeria, at 440 constant 2022 US$ against 400 constant 2022 US$ in India as of 2022.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Algeria and India?
- 40 constant 2022 US$, with Algeria ahead.
- How many years of comparable data are there for Algeria and India?
- 5 years are reported by both, from 2017 to 2022.
- How do Algeria and India rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Algeria ranks 85th and India ranks 87th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.